Tags

Type your tag names separated by a space and hit enter

Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Clin Chem 2011; 57(1):66-75CC

Abstract

BACKGROUND

Sativex(®), a cannabis extract oromucosal spray containing Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), is currently in phase III trials as an adjunct to opioids for cancer pain treatment, and recently received United Kingdom approval for treatment of spasticity. There are indications that CBD modulates THC's effects, but it is unclear if this is due to a pharmacokinetic and/or pharmacodynamic interaction.

METHODS

Cannabis smokers provided written informed consent to participate in this randomized, controlled, double-blind, double-dummy institutional review board-approved study. Participants received 5 and 15 mg synthetic oral THC, low-dose (5.4 mg THC and 5.0 mg CBD) and high-dose (16.2 mg THC and 15.0 mg CBD) Sativex, and placebo over 5 sessions. CBD, THC, 11-hydroxy-THC, and 11-nor- 9-carboxy-THC were quantified in plasma by 2-dimensional GC-MS. Lower limits of quantification were ≤0.25 μg/L.

RESULTS

Nine cannabis smokers completed all 5 dosing sessions. Significant differences (P < 0.05) in maximum plasma concentrations (C(max)) and areas under the curve from 0-10.5 h postdose (AUC(0→10.5)) for all analytes were found between low and high doses of synthetic THC and Sativex. There were no statistically significant differences in C(max), time to maximum concentration or in the AUC(0→10.5) between similar oral THC and Sativex doses. Relative bioavailability was calculated to determine the relative rate and extent of THC absorption; 5 and 15 mg oral THC bioavailability was 92.6% (13.1%) and 98.8% (11.0%) of low- and high-dose Sativex, respectively.

CONCLUSION

These data suggest that CBD modulation of THC's effects is not due to a pharmacokinetic interaction at these therapeutic doses.

Authors+Show Affiliations

Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Intramural

Language

eng

PubMed ID

21078841

Citation

Karschner, Erin L., et al. "Plasma Cannabinoid Pharmacokinetics Following Controlled Oral Delta9-tetrahydrocannabinol and Oromucosal Cannabis Extract Administration." Clinical Chemistry, vol. 57, no. 1, 2011, pp. 66-75.
Karschner EL, Darwin WD, Goodwin RS, et al. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57(1):66-75.
Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S., & Huestis, M. A. (2011). Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clinical Chemistry, 57(1), pp. 66-75. doi:10.1373/clinchem.2010.152439.
Karschner EL, et al. Plasma Cannabinoid Pharmacokinetics Following Controlled Oral Delta9-tetrahydrocannabinol and Oromucosal Cannabis Extract Administration. Clin Chem. 2011;57(1):66-75. PubMed PMID: 21078841.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. AU - Karschner,Erin L, AU - Darwin,W David, AU - Goodwin,Robert S, AU - Wright,Stephen, AU - Huestis,Marilyn A, Y1 - 2010/11/15/ PY - 2010/11/17/entrez PY - 2010/11/17/pubmed PY - 2011/1/21/medline SP - 66 EP - 75 JF - Clinical chemistry JO - Clin. Chem. VL - 57 IS - 1 N2 - BACKGROUND: Sativex(®), a cannabis extract oromucosal spray containing Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), is currently in phase III trials as an adjunct to opioids for cancer pain treatment, and recently received United Kingdom approval for treatment of spasticity. There are indications that CBD modulates THC's effects, but it is unclear if this is due to a pharmacokinetic and/or pharmacodynamic interaction. METHODS: Cannabis smokers provided written informed consent to participate in this randomized, controlled, double-blind, double-dummy institutional review board-approved study. Participants received 5 and 15 mg synthetic oral THC, low-dose (5.4 mg THC and 5.0 mg CBD) and high-dose (16.2 mg THC and 15.0 mg CBD) Sativex, and placebo over 5 sessions. CBD, THC, 11-hydroxy-THC, and 11-nor- 9-carboxy-THC were quantified in plasma by 2-dimensional GC-MS. Lower limits of quantification were ≤0.25 μg/L. RESULTS: Nine cannabis smokers completed all 5 dosing sessions. Significant differences (P < 0.05) in maximum plasma concentrations (C(max)) and areas under the curve from 0-10.5 h postdose (AUC(0→10.5)) for all analytes were found between low and high doses of synthetic THC and Sativex. There were no statistically significant differences in C(max), time to maximum concentration or in the AUC(0→10.5) between similar oral THC and Sativex doses. Relative bioavailability was calculated to determine the relative rate and extent of THC absorption; 5 and 15 mg oral THC bioavailability was 92.6% (13.1%) and 98.8% (11.0%) of low- and high-dose Sativex, respectively. CONCLUSION: These data suggest that CBD modulation of THC's effects is not due to a pharmacokinetic interaction at these therapeutic doses. SN - 1530-8561 UR - https://www.unboundmedicine.com/medline/citation/21078841/abstract/Plasma_cannabinoid_pharmacokinetics_following_controlled_oral_delta9_tetrahydrocannabinol_and_oromucosal_cannabis_extract_administration_ L2 - http://www.clinchem.org/cgi/pmidlookup?view=long&amp;pmid=21078841 DB - PRIME DP - Unbound Medicine ER -